{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:54Z","timestamp":1788869394088,"version":"build-2803163510"},"reference-count":39,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/17\/01"],"award-info":[{"award-number":["16\/17\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Improvements in neonatal and paediatric care in recent decades have increased the survival of children with non-progressive neurological impairment. Respiratory disease in children with neurological impairment is common, with symptoms difficult to manage and lower respiratory tract infection occurring frequently. To reduce these, prophylactic antibiotics are being increasingly used, but the type, duration and dose of antibiotics can vary considerably, and there is limited evidence about their effectiveness in children and young people.<\/jats:p>\n                    <jats:p>A joint United Kingdom and Australia multicentre, randomised, double-blind, placebo-controlled trial comparing 52 weeks of azithromycin to placebo in children and young people with neurological impairment at risk of lower respiratory tract infection (PARROT) was planned to address this gap. PARROT was a multicentre, parallel group, blinded, pragmatic randomised controlled trial of 52-week duration with a planned sample size of 500 (250 in each arm) participants with neurological impairment. The primary outcome was the proportion of children and young people hospitalised with lower respiratory tract infection over the 52-week period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 90 children and young people (62 in Australia, 28 in the United Kingdom) aged 3\u201317 years, with a diagnosed non-progressive, non-neuromuscular neurological impairment, who had persistent respiratory symptoms were randomised (1\u2005:\u20051) to receive azithromycin or placebo. Baseline demographic and clinical characteristics were relatively well balanced across the two treatment groups and countries. Overall, mean (standard deviation) age was 9.2 (4.4) years, with 64% of participants having cerebral palsy, 67% being non-ambulant and 54% being totally tube-fed. At baseline, mean (standard deviation) numbers of hospital admissions with lower respiratory tract infection in the preceding year were 1.8 (2.0)\/year, and general practitioner attendances 3.3 (3.0)\/year.<\/jats:p>\n                    <jats:p>\n                      The PARROT trial was closed early to recruitment due to challenges arising from the COVID-19 pandemic. Sixty-five (72%) participants (azithromycin\n                      <jats:italic>n<\/jats:italic>\n                      \u2005=\u200530, placebo\n                      <jats:italic>n<\/jats:italic>\n                      \u2005=\u200535) completed 52 weeks of treatment and were not withdrawn early from the trial. Regarding the primary outcome, 11 (36.7%) in the azithromycin group were hospitalised with lower respiratory tract infection and 9 (25.7%) in the placebo group [absolute risk reduction 0.11 (95% confidence interval \u22120.12 to 0.33), relative risk\u00a01.43 (95% confidence interval 0.68 to 2.97)]. Analysis of secondary outcome data was limited by the number of missing data, but parent-reported quality of life for young person and parent, sleep amount\/quality for young person and parent, and respiratory symptoms were similar between groups and countries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>As PARROT was stopped early and was consequently underpowered, it is not possible to say whether azithromycin prophylaxis is any more effective than placebo in reducing the proportion of children admitted to hospital with lower respiratory tract infection after a 52-week period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Conclusions and future work<\/jats:title>\n                    <jats:p>Although we cannot comment on the effectiveness of prophylactic antibiotics in this context, we can draw some useful conclusions from this trial. Thus, the importance placed by families on hospitalisation and its prevalence in both treatment groups, even during the pandemic, would suggest that this is an appropriate primary outcome measure for future trials in this high-risk group of children and young people. Furthermore, the high attrition rate and large numbers of missing data, specifically for questionnaire-based outcomes at later follow-up points, should encourage researchers to be mindful of minimising trial burden to families for any future trials wherever possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16\/17\/01.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/gjpm1930","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:57:01Z","timestamp":1759229821000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic antibiotics to prevent chest infections in children with neurological impairment: the PARROT RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-6034","authenticated-orcid":true,"given":"Paul S","family":"McNamara","sequence":"first","affiliation":[{"name":"Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children\u2019s Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-730X","authenticated-orcid":true,"given":"Ashley Paul","family":"Jones","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-3706","authenticated-orcid":true,"given":"Anne","family":"Chang","sequence":"additional","affiliation":[{"name":"Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7808-6096","authenticated-orcid":true,"given":"Kieran","family":"Crabtree","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-7101","authenticated-orcid":true,"given":"Kylie","family":"Crompton","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Murdoch Children\u2019s Research Institute, The Royal Children\u2019s Hospital, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-5275","authenticated-orcid":true,"given":"Sepideh","family":"Dehghani","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-8525","authenticated-orcid":true,"given":"Helen","family":"Eccleson","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-1508","authenticated-orcid":true,"given":"Jo","family":"Fothergill","sequence":"additional","affiliation":[{"name":"Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-6028","authenticated-orcid":true,"given":"Jonathan","family":"Grigg","sequence":"additional","affiliation":[{"name":"Centre for Genomics and Child Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0495-3517","authenticated-orcid":true,"given":"Paul","family":"Gringras","sequence":"additional","affiliation":[{"name":"Guys and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-7382","authenticated-orcid":true,"given":"Adrienne","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Murdoch Children\u2019s Research Institute, The Royal Children\u2019s Hospital, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-505X","authenticated-orcid":true,"given":"Michelle","family":"Heys","sequence":"additional","affiliation":[{"name":"Great Ormond Street Institute of Child Health, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":true,"given":"Dyfrig Arwyn","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation, North Wales Medical School, Bangor University, Bangor, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0210-1468","authenticated-orcid":true,"given":"Gabrielle","family":"McCallum","sequence":"additional","affiliation":[{"name":"Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-825X","authenticated-orcid":true,"given":"Kim","family":"McLennan","sequence":"additional","affiliation":[{"name":"Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9916-507X","authenticated-orcid":true,"given":"Christopher","family":"Morris","sequence":"additional","affiliation":[{"name":"Peninsula Childhood Disability Research Unit (PenCRU), University of Exeter Medical School, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-4666","authenticated-orcid":true,"given":"Amy","family":"Nuttall","sequence":"additional","affiliation":[{"name":"Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children\u2019s Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-7878","authenticated-orcid":true,"given":"Jeremy","family":"Parr","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-9008","authenticated-orcid":true,"given":"Yankier Pijeira","family":"Perez","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation, North Wales Medical School, Bangor University, Bangor, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-7906","authenticated-orcid":true,"given":"Dinah","family":"Reddihough","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Murdoch Children\u2019s Research Institute, The Royal Children\u2019s Hospital, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-0418","authenticated-orcid":true,"given":"Malcolm Gracie","family":"Semple","sequence":"additional","affiliation":[{"name":"Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children\u2019s Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Smallman","sequence":"additional","affiliation":[{"name":"Patient and Public Representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-0425","authenticated-orcid":true,"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[{"name":"Evelina Pharmacy, Guys\u2019 & St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-4458","authenticated-orcid":true,"given":"Katrina","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Monash University and Developmental Paediatrics, Monash Children\u2019s Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"key2026090807085200_ref1-bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5694\/mja2.52487","article-title":"Cerebral palsy in Australia: birth prevalence, 1995\u20132016, and differences by residential remoteness: a population-based register study","volume":"221","author":"Smithers-Sheedy","year":"2024","journal-title":"Med J Aust"},{"key":"key2026090807085200_ref2-bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dmcn.13001","article-title":"Temporal trends in cerebral palsy by impairment severity and birth gestation","volume":"58","author":"Reid","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"key2026090807085200_ref3-bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-3016.2009.01060.x","article-title":"Children with cerebral palsy: severity and trends over time","volume":"23","author":"Surman","year":"2009","journal-title":"Paediatr Perinat Epidemiol"},{"key":"key2026090807085200_ref4-bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpeds.2015.09.064","article-title":"Factors associated with respiratory illness in children and young adults with cerebral palsy","volume":"168","author":"Blackmore","year":"2016","journal-title":"J Pediatr"},{"key":"key2026090807085200_ref5-bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/dmcn.13016","article-title":"Prevalence of symptoms associated with respiratory illness in children and young people with cerebral palsy","volume":"58","author":"Blackmore","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"key2026090807085200_ref6-bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/adc.88.1.75","article-title":"Respiratory problems in children with neurological impairment","volume":"88","author":"Seddon","year":"2003","journal-title":"Arch Dis Child"},{"key":"key2026090807085200_ref7-bib7","first-page":"e39327","article-title":"Risk factors for mortality in patients with cerebral palsy: a systematic review and meta-analysis","volume":"15","author":"Aldharman","year":"2023","journal-title":"Cureus"},{"key":"key2026090807085200_ref8-bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dmcn.15714","article-title":"The cost of respiratory hospitalizations in children with cerebral palsy","volume":"66","author":"Bear","year":"2024","journal-title":"Dev Med Child Neurol"},{"key":"key2026090807085200_ref9-bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1469-8749.2011.04027.x","article-title":"Survival at 19 years of age in a total population of children and young people with cerebral palsy","volume":"53","author":"Westbom","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"key2026090807085200_ref10-bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/adc.2009.180653","article-title":"Use of home oxygen for children in England and Wales","volume":"96","author":"Primhak","year":"2011","journal-title":"Arch Dis Child"},{"key":"key2026090807085200_ref11-bib11","doi-asserted-by":"crossref","first-page":"e1001158","DOI":"10.1371\/journal.pmed.1001158","article-title":"Trends in resource utilization by children with neurological impairment in the United States inpatient health care system: a repeat cross-sectional study","volume":"9","author":"Berry","year":"2012","journal-title":"PLOS Med"},{"key":"key2026090807085200_ref12-bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/PCC.0b013e31819368ac","article-title":"Antibiotic-resistant bacteria and infection in children with cerebral palsy requiring mechanical ventilation","volume":"10","author":"Thorburn","year":"2009","journal-title":"Pediatr Crit Care Med"},{"key":"key2026090807085200_ref13-bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/archdischild-2012-302324","article-title":"Outpatient respiratory management of the child with severe neurological impairment","volume":"98","author":"McCrea","year":"2013","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"key2026090807085200_ref14-bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/archdischild-2015-308350","article-title":"Fifteen-minute consultation: approach to management of respiratory problems in children with neurodisability","volume":"101","author":"Kansra","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"key2026090807085200_ref15-bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"key2026090807085200_ref16-bib16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011530","article-title":"Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under","volume":"2015","author":"Onakpoya","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807085200_ref17-bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","article-title":"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial","volume":"1","author":"Valery","year":"2013","journal-title":"Lancet Respir Med"},{"key":"key2026090807085200_ref18-bib18","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"key":"key2026090807085200_ref19-bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fmicb.2014.00178","article-title":"Antivirulence activity of azithromycin in Pseudomonas aeruginosa","volume":"5","author":"Imperi","year":"2014","journal-title":"Front Microbiol"},{"key":"key2026090807085200_ref20-bib20","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1542\/hpeds.2020-005314","article-title":"Variation in bacterial respiratory culture results in children with neurologic impairment","volume":"11","author":"Warniment","year":"2021","journal-title":"Hosp Pediatr"},{"key":"key2026090807085200_ref21-bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1745-6215-14-53","article-title":"Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial","volume":"14","author":"Chang","year":"2013","journal-title":"Trials"},{"key":"key2026090807085200_ref22-bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fped.2015.00032","article-title":"Three-weekly doses of azithromycin for indigenous infants hospitalized with bronchiolitis: a multicentre, randomized, placebo-controlled trial","volume":"3","author":"McCallum","year":"2015","journal-title":"Front Pediatr"},{"key":"key2026090807085200_ref23-bib23","doi-asserted-by":"crossref","first-page":"e0124627","DOI":"10.1371\/journal.pone.0124627","article-title":"An observational study examining the relationship between respiratory symptoms, airway inflammation and bacteriology in children with severe neurodisability","volume":"10","author":"Trinick","year":"2015","journal-title":"PLOS ONE"},{"key":"key2026090807085200_ref24-bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","article-title":"Valuation of the child health utility 9D index","volume":"30","author":"Stevens","year":"2012","journal-title":"PharmacoEconomics"},{"key":"key2026090807085200_ref25-bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.socscimed.2016.03.042","article-title":"Valuing the Child Health Utility 9D: using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm","volume":"157","author":"Ratcliffe","year":"2016","journal-title":"Soc Sci Med"},{"key":"key2026090807085200_ref26-bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key2026090807085200_ref27-bib27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jval.2020.02.011","article-title":"A review of the methods used to generate utility values in NICE technology assessments for children and adolescents","volume":"23","author":"Hill","year":"2020","journal-title":"Value Health"},{"key":"key2026090807085200_ref28-bib28","volume-title":"England National Cost Collection 2021\/22","author":"National Health Service (NHS)"},{"key":"key2026090807085200_ref29-bib29","volume-title":"Prescription Cost Analysis (PCA) Data","author":"National Health Service (NHS)"},{"key":"key2026090807085200_ref30-bib30","volume-title":"British National Formulary for Children (BNFC)","author":"National Institute for Health and Care Excellence"},{"key":"key2026090807085200_ref31-bib31","volume-title":"Unit Costs of Health and Social Care 2023 Manual","author":"Jones"},{"key":"key2026090807085200_ref32-bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key2026090807085200_ref33-bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"key2026090807085200_ref34-bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1477-7525-5-63","article-title":"The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation","volume":"5","author":"Tennant","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"key2026090807085200_ref35-bib35","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s11136-015-0971-1","article-title":"Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y","volume":"24","author":"Kind","year":"2015","journal-title":"Qual Life Res"},{"key":"key2026090807085200_ref36-bib36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-020-00909-3","article-title":"International valuation protocol for the EQ-5D-Y-3L","volume":"38","author":"Ramos-Go\u00f1i","year":"2020","journal-title":"PharmacoEconomics"},{"key":"key2026090807085200_ref37-bib37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jval.2018.05.002","article-title":"Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) health states: the impact of wording and perspective","volume":"21","author":"Kreimeier","year":"2018","journal-title":"Value Health"},{"key":"key2026090807085200_ref38-bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jval.2015.02.014","article-title":"Assessing the health-related quality of life of Australian adolescents: an empirical comparison of the child health utility 9D and EQ-5D-Y instruments","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"key":"key2026090807085200_ref39-bib39","doi-asserted-by":"crossref","first-page":"e037089","DOI":"10.1136\/bmjopen-2020-037089","article-title":"Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study","volume":"10","author":"Ryan","year":"2020","journal-title":"BMJ Open"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJPM1930\/GJPM1930.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:30:57Z","timestamp":1788867057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/GJPM1930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["10.3310\/GJPM1930"],"URL":"https:\/\/doi.org\/10.3310\/gjpm1930","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"03-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"01-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"09-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}